Subclinical Detection of Diabetic Cardiomyopathy with MicroRNAs: Challenges and Perspectives

The prevalence of cardiac diabetic diseases has been increased around the world, being the most common cause of death and disability among diabetic patients. In particular, diabetic cardiomyopathy is characterized with a diastolic dysfunction and cardiac remodelling without signs of hypertension and...

Full description

Saved in:
Bibliographic Details
Published inJournal of Diabetes Research Vol. 2016; no. 2016; pp. 1 - 12
Main Authors Larico, Martín, Fernandez, Mauricio, Rani, Sweta, León, Luis E., Calligaris, Sebastián D.
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Publishing Corporation 01.01.2016
John Wiley & Sons, Inc
Hindawi Limited
Subjects
Apoptosis
Atherosclerosis
Biomarkers
Biomarkers - metabolism
Cardiomyocytes
Cardiomyopathy
Cardiovascular disease
Congenital diseases
Coronary vessels
Development and progression
Diabetes
Diabetic Cardiomyopathies - diagnosis
Diabetic Cardiomyopathies - genetics
Diabetic Cardiomyopathies - metabolism
Diabetics
DNA methylation
Early Diagnosis
Epigenetics
Fatty acids
Gene expression
Glucose
Heart diseases
Heart failure
Humans
Hypertension
Medical research
Medicine, Experimental
Metabolism
MicroRNA
MicroRNAs
MicroRNAs - genetics
MicroRNAs - metabolism
Plasma
Prognosis
Review
Online AccessGet full text

Cover

More Information
Summary:The prevalence of cardiac diabetic diseases has been increased around the world, being the most common cause of death and disability among diabetic patients. In particular, diabetic cardiomyopathy is characterized with a diastolic dysfunction and cardiac remodelling without signs of hypertension and coronary artery diseases. In an early stage, it is an asymptomatic disease; however, clinical studies demonstrate that diabetic myocardia are more vulnerable to injury derived by acute myocardial infarct and are the worst prognosis for rehabilitation. Currently, biochemical and imaging diagnostic methods are unable to detect subclinical manifestation of the disease (prior to diastolic dysfunction). In this review, we elaborately discuss the current scientific evidences to propose circulating microRNAs as promising biomarkers for early detection of diabetic cardiomyopathy and, then, to identify patients at high risk of diabetic cardiomyopathy development. Moreover, here we summarise the research strategies to identify miRNAs as potential biomarkers, present limitations, challenges, and future perspectives.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Academic Editor: Dirk Westermann
ISSN:2314-6745
2314-6753
DOI:10.1155/2016/6143129